ALP Bio Raises $2.2M Pre-seed To Improve Antibody Development With AI

The round was led by 42CAP, with participation from Venture Kick and strategic angel investors.

Founded in 2025 ALP Bio is building a platform to help drug developers better understand and reduce immunogenicity risks in biologics. By combining immune organoid data with AI, the company enables earlier prediction of anti-drug antibody (ADA) responses during antibody discovery and development.

Immunogenicity remains a major challenge in biologics often emerging only during clinical trials when changes are costly and time-consuming. ALP Bio aims to address this by bringing more clinically relevant insights into earlier stages of development.

Read Also - Moleculent Raises $20M Funding To Scale Cell Communication Mapping Technology

Its hybrid approach integrates lab based immune organoid readouts with machine learning models to support risk assessment and antibody redesign. Built on human tonsil organoid technology and advanced AI models the platform supports candidate screening, risk stratification and sequence optimisation while preserving therapeutic effectiveness.

ALP Bio is now working with pharmaceutical and biotech partners on early-access collaborations, focusing on improving candidate selection and reducing late-stage development risks.

“Immunogenicity is one of the largest hidden costs in biologics, and the industry has accepted late-stage surprises as the norm for too long. We believe this risk should be measured and reduced years earlier than it is today. This financing lets us scale the experimental and computational foundation of our platform and partner with teams who want to make antibody development more predictable from the start,” says Dr Christian Vahlensieck, CEO of ALP Bio AG.

About ALP Bio AG

ALP Bio AG a biotech company building an immune organoid and AI platform to predict immunogenicity risks in biologics. It combines human immune data with generative AI to help developers reduce anti drug antibody risks early. Headquartered in Switzerland it operates globally with partners across the biotech industry.